KLRA (Kailera Therapeutics) Interest Expense: $ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
12 GF Score
Price $12.74
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics Interest Expense?

Kailera Therapeutics KLRA -1.24% 12 Interest Expense is $ Mil as of Jun. 2026. GuruFocus rates KLRA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kailera Therapeutics's interest expense for the three months ended in Jun. 2026 was $ 0.00 Mil. Kailera Therapeutics does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in Jun. 2026.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kailera Therapeutics's Operating Income for the three months ended in Jun. 2026 was $ -121.37 Mil. Kailera Therapeutics's Interest Expense for the three months ended in Jun. 2026 was $ 0.00 Mil. GuruFocus does not calculate Kailera Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kailera Therapeutics  (NAS:KLRA) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kailera Therapeutics's Interest Expense for the three months ended in Jun. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2026 was $-121.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was $0.00 Mil.

Kailera Therapeutics's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Kailera Therapeutics had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Kailera Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Kailera Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Interest Expense Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
Interest Expense
0.00 0.00

Kailera Therapeutics Quarterly Data
Jun25 Mar26 Jun26
Interest Expense 0.00 0.00 0.00
KLRA
12GF Score
Kailera Therapeutics Inc KLRA
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $ Mil mean?
Kailera Therapeutics (KLRA) has a Interest Expense of $ Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kailera Therapeutics and its competitors.
Is Kailera Therapeutics' Interest Expense too high?
Kailera Therapeutics' current Interest Expense is $ Mil. Overall, Kailera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Interest Expense compare to VCEL and ADMA?
Kailera Therapeutics' Interest Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current Interest Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Interest Expense of $ Mil. The current Interest Expense is $ Mil. Kailera Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Interest Expense is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
12GF Score

Get the complete analysis for KLRA

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.74
Price